hackint0sh/temp-data huggingface dataset:
protocolSection identificationModule nctId: NCT06319664, orgStudyIdInfo id: sjnkzzj, briefTitle: Clinical Outcomes and Decision-making Choice of Skull Base Approaches for Petroclival Meningiomas, statusModule overallStatus: COMPLETED, startDateStruct date: 2021-05-27, primaryCompletionDateStruct date: 2021-08-10, completionDateStruct date: 2021-09-10, studyFirstPostDateStruct date: 2024-03-20, lastUpdatePostDateStruct date: 2024-03-20, sponsorCollaboratorsModule leadSponsor name: Xiangya Hospital of Central South University, class: OTHER, descriptionModule briefSummary: Petroclival meningioma (PCM) is a technically challenging lesion. We aimed to analyze the role of various skull base approaches and evaluate the therapeutic outcomes guided by the modified classification. We retrospectively analyzed the clinical characteristics, surgical approaches, outcomes and follow-up data from 179 cases of PCM from January 2011 to December 2020. We modified the previous classification into updated five types with two subtypes: clivus type (CV), petroclival type (PC), petroclivosphenoidal type (PC-S), sphenopetroclival type (S-PC) with two subtypes of S-PC I and S-PC II and central skull base type (CSB). Statistical analysis was performed using IBM SPSS Statistical Package 21.0. The t-test was performed to clinical data comparisons between the two groups and the ANOVA test was used to compare the difference between multiple groups. P \< 0.05 was considered statistically significant., conditionsModule conditions: Skull Base Meningioma, designModule studyType: OBSERVATIONAL, designInfo observationalModel: CASE_CONTROL, timePerspective: RETROSPECTIVE, enrollmentInfo count: 179, type: ACTUAL, armsInterventionsModule interventions name: retrosigmoid approach (RSA), interventions name: subtemporal transtentorial transpetrosal approach (STTA), interventions name: extended pterional transtentorial approach (EPTA), interventions name: pretemporal trancavernous anterior transpetrosal approach (PTCA), interventions name: presigmoid combined supra-infratentorial approach (PCA), interventions name: inoperable, outcomesModule primaryOutcomes measure: QOL were assessed and measured using the Karnofsky Performance Scale (KPS) score, eligibilityModule sex: ALL, minimumAge: 15 Years, maximumAge: 73 Years, stdAges: CHILD, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Xiangya Hospital, Central South University, city: Changsha, state: Hunan, zip: 410000, country: China, geoPoint lat: 28.19874, lon: 112.97087, hasResults: False
protocolSection identificationModule nctId: NCT06319651, orgStudyIdInfo id: REC/RCR&AHS/23/0360, briefTitle: Effects of Lower Limb Resistance Band Exercises in Phase 1 Cardiac Rehabilitation, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-03-01, primaryCompletionDateStruct date: 2024-06-05, completionDateStruct date: 2024-06-15, studyFirstPostDateStruct date: 2024-03-20, lastUpdatePostDateStruct date: 2024-03-27, sponsorCollaboratorsModule leadSponsor name: Riphah International University, class: OTHER, descriptionModule briefSummary: This study will be randomized controlled trial with non-probability purposive sampling. Study conducted among post CABG patients. Sample size will be 56, 28 in each group. Outcome will be measured by using 6 minute walk test, Spirometry (FVC, FEV1/FVC and PEF), Functional Independence Measure., conditionsModule conditions: Cardiovascular Diseases, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: Randomized controlled trial (RCT). Pre \& Post data collection, primaryPurpose: OTHER, maskingInfo masking: SINGLE, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 56, type: ESTIMATED, armsInterventionsModule interventions name: Lower Limb Resistance Band Exercises, interventions name: Routine Phase 1 cardiac rehabilitation, outcomesModule primaryOutcomes measure: Functional Independence Measure, primaryOutcomes measure: 6 Minute Walk Test, primaryOutcomes measure: Forced expiratory volume (FEV1), primaryOutcomes measure: Forced vital capacity (FVC), primaryOutcomes measure: FEV1/FVC ratio, eligibilityModule sex: ALL, minimumAge: 35 Years, maximumAge: 60 Years, stdAges: ADULT, contactsLocationsModule locations facility: Rehmatul lil Alameen Institute of cardiology, status: RECRUITING, city: Lahore, state: Punjab, zip: 42000, country: Pakistan, contacts name: Dr. Fareed Ahmad, MBBS, role: CONTACT, phone: 04299330101, email: ms.raic@pessi.punjab.gov.pk, contacts name: Afifa Shoaib, DPT, role: SUB_INVESTIGATOR, geoPoint lat: 31.558, lon: 74.35071, hasResults: False
protocolSection identificationModule nctId: NCT06319638, orgStudyIdInfo id: SGB TBI, briefTitle: Efficacy of Stellate Ganglion Block in Traumatic Brain Injury Patients, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05, primaryCompletionDateStruct date: 2024-12, completionDateStruct date: 2024-12, studyFirstPostDateStruct date: 2024-03-20, lastUpdatePostDateStruct date: 2024-03-20, sponsorCollaboratorsModule leadSponsor name: Copka Sonpashan, class: OTHER_GOV, descriptionModule briefSummary: The goal of this or clinical trial is to explore efficacy of stellate ganglion block on dysphagia and activities of daily living in Traumatic Brain Injury Patients. The main question it aims to answer are:Can stellate ganglion block improve the dysphagia and activities of daily living in Traumatic Brain Injury Patients.Traumatic Brain Injury Patients will be divided into the the control group and observation group evenly. All the patients were provided with routine therapy, while the patients in the observation group were given stellate ganglion block. The swallowing function, and activities of daily living of the two groups of patients before and after treatment were evaluated., conditionsModule conditions: Traumatic Brain Injury, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: SINGLE, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 100, type: ESTIMATED, armsInterventionsModule interventions name: Rehabilitation therapy, interventions name: Stellate ganglion block, interventions name: Placebo block, interventions name: Lidocaine Hydrochloride, outcomesModule primaryOutcomes measure: Penetration-Aspiration Scale, secondaryOutcomes measure: Modified Barthel Index, secondaryOutcomes measure: Swallowing duration, secondaryOutcomes measure: Functional Oral Intake Scale, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, hasResults: False
protocolSection identificationModule nctId: NCT06319625, orgStudyIdInfo id: SGB PARKINSON, briefTitle: Effectiveness of Stellate Ganglion Block in Patients Diagnosed With Parkinson's Disease, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-03, primaryCompletionDateStruct date: 2024-12, completionDateStruct date: 2024-12, studyFirstPostDateStruct date: 2024-03-20, lastUpdatePostDateStruct date: 2024-03-20, sponsorCollaboratorsModule leadSponsor name: Copka Sonpashan, class: OTHER_GOV, descriptionModule briefSummary: The goal of this or clinical trial is to explore efficacy of stellate ganglion block on dysphagia and activities of daily living in patients with Parkinson's disease. The main question it aims to answer are:• Can stellate ganglion block improve the dysphagia and activities of daily living in patients with Parkinson's disease.Participants will be divided into the the control group and observation group evenly. All the patients were provided with routine therapy, while the patients in the observation group were given stellate ganglion block. The swallowing function, and activities of daily living of the two groups of patients before and after treatment were evaluated., conditionsModule conditions: Parkinson Disease, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: QUADRUPLE, whoMasked: PARTICIPANT, whoMasked: CARE_PROVIDER, whoMasked: INVESTIGATOR, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 80, type: ESTIMATED, armsInterventionsModule interventions name: Rehabilitation therapy, interventions name: Stellate ganglion block, interventions name: Lidocaine hydrochloride, interventions name: Placebo injection, outcomesModule primaryOutcomes measure: Penetration-Aspiration Scale, secondaryOutcomes measure: Modified Barthel Index, secondaryOutcomes measure: Functional Oral Intake Scale, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, hasResults: False
protocolSection identificationModule nctId: NCT06319612, orgStudyIdInfo id: SGB OSA DOUBLE BLIND, briefTitle: Effectiveness of Stellate Ganglion Block for the Treatment of Obstructive Sleep Apnea, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-03, primaryCompletionDateStruct date: 2024-12, completionDateStruct date: 2024-12, studyFirstPostDateStruct date: 2024-03-20, lastUpdatePostDateStruct date: 2024-03-20, sponsorCollaboratorsModule leadSponsor name: Copka Sonpashan, class: OTHER_GOV, descriptionModule briefSummary: The goal of this clinical trial is to test the efficacy of stellate ganglion block in Obstructive Sleep Apnea. The main question it aims to answer are:• Can stellate ganglion block improve Obstructive Sleep Apnea? Patients were randomly divided into two groups, all provided with routine therapy. Based on this, the experimental group was given stellate ganglion block. The video fluoroscopic swallowing study was done to test the swallowing function before and after the study., conditionsModule conditions: Obstructive Sleep Apnea, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: QUADRUPLE, whoMasked: PARTICIPANT, whoMasked: CARE_PROVIDER, whoMasked: INVESTIGATOR, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 80, type: ESTIMATED, armsInterventionsModule interventions name: routine rehabilitation treatment, interventions name: Stellate ganglion block, interventions name: Lidocaine Hydrochloride, interventions name: Placebo injection, outcomesModule primaryOutcomes measure: Epworth Sleepiness Scale, secondaryOutcomes measure: Apnea-Hypopnea Index, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, hasResults: False
protocolSection identificationModule nctId: NCT06319599, orgStudyIdInfo id: SGB GUDU, briefTitle: Stellate Ganglion Block in Children With Autistic Disorder, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-03, primaryCompletionDateStruct date: 2024-12, completionDateStruct date: 2024-12, studyFirstPostDateStruct date: 2024-03-20, lastUpdatePostDateStruct date: 2024-03-20, sponsorCollaboratorsModule leadSponsor name: Copka Sonpashan, class: OTHER_GOV, descriptionModule briefSummary: The goal of this clinical trial is to explore efficacy of stellate ganglion block Children with Autistic Disorder. The main question it aims to answer is:Can stellate ganglion block improve the Autistic Disorder in children? Children with Autistic Disorder will be divided into the control group and experimental group evenly. All the patients were provided with routine therapy, while the patients in the experimental group were given stellate ganglion block. The Childhood Autism Rating Scale of the two groups of patients before and after treatment are evaluated., conditionsModule conditions: Autistic Disorder, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: QUADRUPLE, whoMasked: PARTICIPANT, whoMasked: CARE_PROVIDER, whoMasked: INVESTIGATOR, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 80, type: ESTIMATED, armsInterventionsModule interventions name: Routine therapy, interventions name: Stellate ganglion block, interventions name: Lidocaine hydrochloride, interventions name: placebo injection, outcomesModule primaryOutcomes measure: Childhood Autism Rating Scale, secondaryOutcomes measure: Children's Communication Checklist, secondaryOutcomes measure: Social Interaction Assessment Scale, secondaryOutcomes measure: Children's Depression Inventory, secondaryOutcomes measure: Childhood Anxiety Sensitivity Index, eligibilityModule sex: ALL, minimumAge: 4 Months, maximumAge: 8 Years, stdAges: CHILD, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06319586, orgStudyIdInfo id: Soh-Med-24-02-08MS, briefTitle: The Radial Forearm Flap In Reconstruction Of Upper Limb Injuries, statusModule overallStatus: COMPLETED, startDateStruct date: 2024-02-07, primaryCompletionDateStruct date: 2024-02-07, completionDateStruct date: 2024-02-07, studyFirstPostDateStruct date: 2024-03-20, lastUpdatePostDateStruct date: 2024-03-20, sponsorCollaboratorsModule leadSponsor name: Sohag University, class: OTHER, descriptionModule briefSummary: The radial forearm flap is a very useful and versatile flap with a long vascular pedicle and a thin, pliable skin. It's used in reconstruction of the mutilated hand as a reverse pedicled flap. The dominant pedicle is the radial artery, with venous outflow through the dual system of the venae comitantes and cephalic vein. Sensory innervation may be derived from the medial and lateral antebrachial cutaneous nerves. The radial forearm flap offers the advantage of a large area of donor tissue from the involved extremity with the potential for inclusion of bone, nerve, and tendon grafts. Sacrifice of the radial artery has not been associated with significant patient symptoms However, the donor defect can be troublesome, frequently requiring skin grafting directly over the paratenon of the flexor tendons, producing an undesirable donor site appearance, conditionsModule conditions: for Upper Limb Soft Tissue Coverage, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 20, type: ACTUAL, armsInterventionsModule interventions name: Radial Forearm Flap, outcomesModule primaryOutcomes measure: Viability of the flap, eligibilityModule sex: ALL, minimumAge: 5 Years, maximumAge: 80 Years, stdAges: CHILD, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Sohag University hospitals, city: Sohag, country: Egypt, geoPoint lat: 26.55695, lon: 31.69478, hasResults: False
protocolSection identificationModule nctId: NCT06319573, orgStudyIdInfo id: 2305-UNIVF-070-DC, briefTitle: The Impact of Personalized Prognostic Counseling on IVF Patient's Experience and Treatment Utilization, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-03-19, primaryCompletionDateStruct date: 2025-08-31, completionDateStruct date: 2026-02-28, studyFirstPostDateStruct date: 2024-03-20, lastUpdatePostDateStruct date: 2024-04-19, sponsorCollaboratorsModule leadSponsor name: Ginefiv, class: OTHER, collaborators name: Univfy Inc., descriptionModule briefSummary: This study will be conducted in two phases. In the first phase, research subjects will be assigned to receive standard counseling. In the second phase, research subjects will receive Univfy counseling., conditionsModule conditions: Infertility, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NON_RANDOMIZED, interventionModel: SEQUENTIAL, primaryPurpose: OTHER, maskingInfo masking: NONE, enrollmentInfo count: 366, type: ESTIMATED, armsInterventionsModule interventions name: Counseling Supported by Univfy® Report, interventions name: Standard Counseling, outcomesModule primaryOutcomes measure: Treatment utilization (conversion) rate in the two groups, primaryOutcomes measure: Patient experience responses, primaryOutcomes measure: Validation of Univfy prediction upon CLBdR, primaryOutcomes measure: Retention Rate, primaryOutcomes measure: Time to Pregnancy, secondaryOutcomes measure: Self-reported satisfaction related to psychological support and cost of treatment, eligibilityModule sex: FEMALE, minimumAge: 18 Years, maximumAge: 39 Years, stdAges: ADULT, contactsLocationsModule locations facility: Ginefiv S.L, status: RECRUITING, city: Barcelona, zip: 08015, country: Spain, contacts name: Xinxin Lin Miao, role: CONTACT, phone: +34930400200, email: x.lin@ginefiv.com, contacts name: Xinxin Lin Miao, MD, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 41.38879, lon: 2.15899, locations facility: Ginefiv S.L, status: RECRUITING, city: Madrid, zip: 28018, country: Spain, contacts name: Joaquin Llacer, role: CONTACT, phone: +34900908988, email: j.llacer@ginefiv.com, contacts name: Joaquin Llacer, MD, PhD, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 40.4165, lon: -3.70256, hasResults: False
protocolSection identificationModule nctId: NCT06319547, orgStudyIdInfo id: Soh-Med-24-02-07MS, briefTitle: Comparing Outcome of Thoracocentesis and Pigtail Catheter Drainage in Treatment of Patients With Hepatic Hydrothorax, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-02-20, primaryCompletionDateStruct date: 2025-02, completionDateStruct date: 2025-03, studyFirstPostDateStruct date: 2024-03-20, lastUpdatePostDateStruct date: 2024-03-20, sponsorCollaboratorsModule leadSponsor name: Sohag University, class: OTHER, descriptionModule briefSummary: Hepatic hydrothorax (HH) is a pleural effusion that develops in a patient with cirrhosis and portal hypertension in the absence of cardiopulmonary disease (Lv et al., 2018). Several factors are known to contribute to the development of effusion; the most accepted mechanism of which is the direct delivery of ascitic fluid from the peritoneal cavity to the pleural cavity by "positive" intra-abdominal pressure and a "negative" intrathoracic pressure of the pleural cavity through microscopic congenital diaphragmatic defects (Han et al., 2022)., conditionsModule conditions: Hepatic Hydrothorax, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 100, type: ESTIMATED, armsInterventionsModule interventions name: Thoracocentasis, outcomesModule primaryOutcomes measure: percentage of empyema in patients with hepatic hydrothorax after thoracocentesis, eligibilityModule sex: ALL, stdAges: CHILD, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Sohag University hospitals, status: RECRUITING, city: Sohag, country: Egypt, contacts name: Magdy M Amin, Professor, role: CONTACT, geoPoint lat: 26.55695, lon: 31.69478, hasResults: False
protocolSection identificationModule nctId: NCT06319534, orgStudyIdInfo id: SGB-ZHENQIU, briefTitle: Stellate Ganglion Block in Bulbar Palsy, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-03, primaryCompletionDateStruct date: 2024-12, completionDateStruct date: 2024-12, studyFirstPostDateStruct date: 2024-03-20, lastUpdatePostDateStruct date: 2024-03-20, sponsorCollaboratorsModule leadSponsor name: Copka Sonpashan, class: OTHER_GOV, descriptionModule briefSummary: This is a randomized controlled study, including dysphagic patients with bulbar palsy after ischemic stroke who were received in the department of rehabilitation medicine in 3 hospitals in China. All patients are randomly allocated to the observation group or the control group. Both groups are provided with comprehensive rehabilitation. Besides, the observation group additionally undergoes the stellate ganglion block. At admission and after 10-day treatment, video fluoroscopic swallowing study, and penetration-aspiration scale, Functional Oral Intake Scale, Flexible laryngoscope are used to assess swallowing function., conditionsModule conditions: Bulbar Palsy, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: QUADRUPLE, whoMasked: PARTICIPANT, whoMasked: CARE_PROVIDER, whoMasked: INVESTIGATOR, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 80, type: ESTIMATED, armsInterventionsModule interventions name: Comprehensive rehabilitation, interventions name: Stellate ganglion block, interventions name: Lidocaine Hydrochloride, interventions name: placebo injection, outcomesModule primaryOutcomes measure: Penetration-Aspiration Scale, secondaryOutcomes measure: Functional Oral Intake Scale, secondaryOutcomes measure: Murray secretion severity scale, secondaryOutcomes measure: Yale pharyngeal residue severity rating scale, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06319521, orgStudyIdInfo id: SGB-REFLUX, briefTitle: Stellate Ganglion Block on Gastroesophageal Reflux Disease, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-03, primaryCompletionDateStruct date: 2024-12, completionDateStruct date: 2024-12, studyFirstPostDateStruct date: 2024-03-20, lastUpdatePostDateStruct date: 2024-03-20, sponsorCollaboratorsModule leadSponsor name: Copka Sonpashan, class: OTHER_GOV, descriptionModule briefSummary: The goal of this clinical trial is to explore Clinical Effect of Stellate Ganglion Block on Gastroesophageal Reflux Disease. The main question it aims to answer is:• Can stellate ganglion block improve gastroesophageal reflux symptoms better on the basis of rehabilitation training? Participants will be randomly allocated into the control group or the experimental group, all under rehabilitation treatment, the experimental group will be given Stellate Ganglion Block once a day additionally. The study lasts 20 days for each participant. Researchers will compare the Gastroesophageal Reflux Disease Questionnaire, Pressure pain threshold, Self-Evaluation Questionnaire for Gastroesophageal Reflux Disease, to see if the Stellate Ganglion Block can help improve the symptom., conditionsModule conditions: Gastroesophageal Reflux Disease, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: QUADRUPLE, whoMasked: PARTICIPANT, whoMasked: CARE_PROVIDER, whoMasked: INVESTIGATOR, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 80, type: ESTIMATED, armsInterventionsModule interventions name: Rehabilitation therapy, interventions name: Stellate ganglion block, interventions name: Lidocaine hydrochloride, interventions name: Placebo injection, outcomesModule primaryOutcomes measure: Gastroesophageal Reflux Disease Questionnaire, secondaryOutcomes measure: Pressure pain threshold, secondaryOutcomes measure: Modified Mayo Clinic Dysphagia-30 questionnaire, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 80 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False